Guangdong Zhongsheng Pharmaceutical (002317.SZ): The active pharmaceutical ingredient Brexpiprazole has received approval for its market application.

date
17:28 31/07/2026
avatar
GMT Eight
Zhongsheng Pharmaceutical (002317.SZ) announced that its wholly-owned subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., recently received the approval notice for the marketing application of the raw material drug Brexpiprazole from the National Medical Products Administration. Brexpiprazole formulation is used for the treatment of schizophrenia in adults.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its wholly-owned subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., has recently received the Drug Approval Notification for the active pharmaceutical ingredient Brupiprazole issued by the National Medical Products Administration. Brupiprazole formulations are used for the treatment of adult schizophrenia. The approval of the active pharmaceutical ingredient Brupiprazole indicates that it has met the relevant drug evaluation technical standards in the country and is authorized for use and sale in domestic formulations. This will enrich the companys specialty active pharmaceutical ingredient product pipeline and support the company's expansion in the research, development, and sales of this product.